Immix Biopharma (IMMX) News Today $2.66 +0.04 (+1.72%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Immix Biopharma, Inc. to Present at Guggenheim Healthcare Innovation Conference on November 11, 2025October 14 at 9:10 AM | quiverquant.comQImmix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation ConferenceOctober 14 at 8:45 AM | globenewswire.comImmix Biopharma's (IMMX) Sell (D-) Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comImmix Biopharma, Inc. to Present NXC-201 Abstract at ASH 67th Annual MeetingOctober 6, 2025 | quiverquant.comQImmix Biopharma files to sell 6.85M shares of common stock for holdersOctober 6, 2025 | msn.comContrasting Immix Biopharma (NASDAQ:IMMX) and MiNK Therapeutics (NASDAQ:INKT)October 5, 2025 | americanbankingnews.comImmix Biopharma, Inc. to Host Investor Meetings at 37th Annual Piper Sandler Healthcare ConferenceOctober 1, 2025 | quiverquant.comQImmix Biopharma to Present at the 37th Annual Piper Sandler Healthcare ConferenceOctober 1, 2025 | globenewswire.comImmix Biopharma, Inc.: Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2September 19, 2025 | finanznachrichten.deImmix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2September 18, 2025 | globenewswire.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest UpdateSeptember 14, 2025 | marketbeat.comImmix Biopharma (NASDAQ:IMMX) Given New $8.00 Price Target at HC WainwrightSeptember 14, 2025 | marketbeat.comImmix Biopharma price target raised to $8 from $7 at H.C. WainwrightSeptember 12, 2025 | msn.comImmix Biopharma appoints Nancy Chang to board of directorsSeptember 12, 2025 | msn.comNancy T. Chang Joins Immix Biopharma Board of Directors as Founding Member of Goose CapitalSeptember 11, 2025 | quiverquant.comQNancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of DirectorsSeptember 11, 2025 | globenewswire.comImmix Biopharma receives strategic investment from Goose CapitalSeptember 9, 2025 | msn.comImmix Biopharma Completes Private Placement TransactionSeptember 9, 2025 | msn.comImmix Biopharma Secures Strategic Investment from Goose Capital and Dr. Nancy T. Chang to Advance Innovative Cell TherapiesSeptember 8, 2025 | quiverquant.comQImmix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. ChangSeptember 8, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Lowered to Sell Rating by Wall Street ZenSeptember 1, 2025 | marketbeat.comZacks Research Downgrades Immix Biopharma (NASDAQ:IMMX) to HoldAugust 29, 2025 | marketbeat.comImmix Biopharma, Inc. to Host Investor Meetings at Stifel 2025 Healthcare ConferenceAugust 25, 2025 | quiverquant.comQImmix Biopharma to Present at the Stifel 2025 Healthcare ConferenceAugust 25, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings ResultsAugust 11, 2025 | marketbeat.comImmix Biopharma Loses US$9.2m Market Value But Insiders See Windfall Of US$19kAugust 8, 2025 | finance.yahoo.comImmix Biopharma Announces Other Serious Diseases StrategyAugust 6, 2025 | globenewswire.comImmix Biopharma (IMMX) Projected to Post Earnings on MondayAugust 5, 2025 | marketbeat.comImmix Biopharma (NASDAQ:IMMX) Trading 1.9% Higher - Still a Buy?July 31, 2025 | marketbeat.comImmix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication ExpansionJuly 11, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% - Here's WhyJuly 9, 2025 | marketbeat.comImmix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - MorningstarJuly 8, 2025 | morningstar.comMImmix Biopharma, Inc.: Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL AmyloidosisJuly 8, 2025 | finanznachrichten.deImmix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL AmyloidosisJuly 7, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street ZenJune 27, 2025 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 35.6% in MayJune 17, 2025 | marketbeat.comImmix Biopharma Attends FDA CEO Forum in Washington DCJune 6, 2025 | globenewswire.comH.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 TrialJune 6, 2025 | msn.comHC Wainwright Predicts Stronger Earnings for Immix BiopharmaJune 6, 2025 | marketbeat.comBrokers Issue Forecasts for Immix Biopharma Q1 EarningsJune 5, 2025 | marketbeat.comImmix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025June 5, 2025 | nasdaq.comImmix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis TrialJune 4, 2025 | msn.comImmix Biopharma (NASDAQ:IMMX) Receives "Buy" Rating from HC WainwrightJune 4, 2025 | marketbeat.comImmix Biopharma Enters At The Market Offering AgreementJune 3, 2025 | tipranks.comImmix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL AmyloidosisJune 3, 2025 | globenewswire.comImmix Biopharma Inc.May 27, 2025 | wsj.comImmix Biopharma (NASDAQ:IMMX) Trading Up 15.3% - Should You Buy?May 25, 2025 | marketbeat.comImmix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL AmyloidosisMay 24, 2025 | nasdaq.comImmix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2May 23, 2025 | globenewswire.comImmix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL AmyloidosisMay 22, 2025 | globenewswire.com Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMMX Media Mentions By Week IMMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMX News Sentiment▼0.900.72▲Average Medical News Sentiment IMMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMX Articles This Week▼32▲IMMX Articles Average Week Get the Latest News and Ratings for IMMX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Immix Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Voyager Therapeutics News Today Tectonic Therapeutic News Today Alpha Teknova News Today Abeona Therapeutics News Today Zura Bio News Today Ventyx Biosciences News Today Immuneering News Today Humacyte News Today Tiziana Life Sciences News Today Cartesian Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
